Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ternant, David, Le Tilly, Olivier, Picon, Laurence, Moussata, Driffa, Passot, Christophe, Bejan-Angoulvant, Theodora, Desvignes, Céline, Mulleman, Denis, Goupille, Philippe, Paintaud, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623740/
https://www.ncbi.nlm.nih.gov/pubmed/34834236
http://dx.doi.org/10.3390/pharmaceutics13111821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623740/
https://www.ncbi.nlm.nih.gov/pubmed/34834236
http://dx.doi.org/10.3390/pharmaceutics13111821

Ejemplares similares